Jacobs Levy Equity Management
BDTX icon

Jacobs Levy Equity Management’s Black Diamond Therapeutics BDTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,754
Closed -$132K – 999
2021
Q4 		$132K Buy
+24,754
New +$173K ﹤0.01% 950
2021
Q1 		– Sell
-13,801
Closed -$442K – 1014
2020
Q4 		$442K Buy
+13,801
New +$453K ﹤0.01% 871

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's BDTX Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2022, closing a stake of 24,754 shares — an estimated $132K sold.

Jacobs Levy Equity Management first reported a position in BDTX in Q4 2020 and held it in 2 quarters. The position peaked at $442K in Q4 2020. 87 funds tracked by Wall St. Rank hold BDTX as of Q1 2022.

  • Jacobs Levy Equity Management reported no remaining Black Diamond Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 24,754 Black Diamond Therapeutics shares in Q1 2022, an estimated $132K.
  • Jacobs Levy Equity Management first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Black Diamond Therapeutics position peaked at $442K in Q4 2020.
  • 87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.